» Articles » PMID: 28196286

Psoralen with Ultraviolet A-induced Apoptosis of Cutaneous Lymphoma Cell Lines is Augmented by Type I Interferons Via the JAK1-STAT1 Pathway

Overview
Date 2017 Feb 15
PMID 28196286
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Photochemotherapy with psoralen and ultraviolet A (PUVA), with or without adjuvant interferon-α (IFN-α), is a first-line therapy for early-stage mycosis fungoides and other forms of cutaneous T-cell lymphoma (CTCL). However, the mechanism by which PUVA with IFN-α work in CTCL is poorly understood.

Purpose: To develop a model to investigate the mechanisms of PUVA and PUVA with IFN-α in CTCL cells.

Methods: An in vitro model to study the molecular mechanisms of PUVA was created using two different CTCL cell lines, MyLa, which has functional p53, and HuT-78, in which p53 is inactivated due to a homozygous nonsense mutation.

Results: PUVA caused G2/M cell cycle block and apoptosis of MyLa and HuT-78 accompanied by increase in the expression of the mitochondrial pro-apoptotic genes Bax, BAK, and PUMA and a downregulation in anti-apoptotic Bcl-2. p53 was induced and c-Myc was repressed by PUVA, but neither were essential for PUVA-induced apoptosis. IFN-α augmented PUVA-induced apoptosis via the JAK1 pathway, and this activity could be inhibited by ruxolitinib.

Conclusion: PUVA induces p53-independent apoptosis in CTCL cell lines, and this process is augmented by type I interferons via the JAK1 pathway.

Citing Articles

The complex development of psoralen-interstrand crosslink resistance in requires AcrR inactivation, retention of a sequence, and one of three MarA, SoxS, or Rob global regulators.

Worley T, Asal A, Cooper L, Courcelle C, Courcelle J bioRxiv. 2024; .

PMID: 39677732 PMC: 11642870. DOI: 10.1101/2024.12.03.626702.


Anti-tumor effect and hepatotoxicity mechanisms of psoralen.

Meng D, Dong Y, Shang Q, Sun Z Front Pharmacol. 2024; 15:1442700.

PMID: 39161897 PMC: 11331265. DOI: 10.3389/fphar.2024.1442700.


Shining a Light on Prostate Cancer: Photodynamic Therapy and Combination Approaches.

Wahnou H, Youlyouz-Marfak I, Liagre B, Sol V, Oudghiri M, Duval R Pharmaceutics. 2023; 15(6).

PMID: 37376215 PMC: 10302598. DOI: 10.3390/pharmaceutics15061767.


Mutations in AcrR and RNA Polymerase Confer High-Level Resistance to Psoralen-UVA Irradiation.

Worley T, Weber E, Acott J, Shimpi R, Cole J, Courcelle C J Bacteriol. 2023; 205(6):e0012623.

PMID: 37249472 PMC: 10294641. DOI: 10.1128/jb.00126-23.


An Overview of Potential Natural Photosensitizers in Cancer Photodynamic Therapy.

Aziz B, Aziz I, Khurshid A, Raoufi E, Nasr Esfahani F, Jalilian Z Biomedicines. 2023; 11(1).

PMID: 36672732 PMC: 9855789. DOI: 10.3390/biomedicines11010224.